SlideShare a Scribd company logo
Glomerulonephritides
(Nephritic and Nephrotic)
Dr Paul Mashanga
Paediatric Nephrologist
Case
 A 9 yr old presents with h/o of seizures for 1 day.
Mom gives a history that the boy was well until 2
days ago when he started c/o a headache,
swelling of feet and eyes, and passing tea
colored urine. No h/o travel but mom says the boy
had sore throat 2 weeks ago
Introduction
 Glomerulonephritis, as the term states, is
inflammation of the glomerulus
 Acute Glomerular injury with the following
features:
 Haematuria (Microscopic or Macroscopic)
 Hypertension (due to water and salt retention)
 AKI (Oliguria, Uraemia, elevated creatinine)
 Oedema (Peripheral or Pulmonary)
 The major underlying pathology is inflammation of the
glomerulus
 The primary pathology can be in the kidney, or it can
be a consequence of systemic disorders
Etiology Causative agent Examples
Post-Infectious
(Immune complex mediated
following infection)
Bacterial
Post-Streptococcal
(80% of cases)
S. aureus, S. pneumoniae, M,
pneumoiae, E. coli, Sypilis, TB
Viral EBV, CMV, HSV, VZV, Hepatitis
B and C, HIV
Parasites Malaria, Schistosomiasis,
Toxoplamosis, Trypanosomiasis
Fungi Candida, Aspergillus,
Cryptococcus, etc
Autoimmune Immune Complex Mediated
Systemic Lupus Erythematosus
Ig A vasculitis (HSP)
IgA Nephropathy
Anti GBM antibodies Anti GBM
Pauciimmune ANCA Vasculitis GPA, MPA
Pathophysiology
 Depends on the underlying cause
 There is a structural disruption of the glomerular basement
membrane
 Glomerular filtration barrier (GFB) is formed by a meshwork
of laminin, proteoglycans, and type IV collagen
 The GFB allows the filtration of water and small and
medium-sized solutes
 The three layers of the glomerular filtration barrier are the
endothelium, glomerular basement membrane (GBM), and
podocytes
Pathophysiology
Pathophysiology
 The GFB can be damaged by various
mechanisms
 Direct damage to the endothelial cell layer
 Deposition of immune complex in subendothelial,
subepithelial, and mesangial space
 Disruption of glomerular basement membrane by
primary renal or secondary systemic diseases
 Damage to the podocytes' cellular layer
Pathophysiology
ofAPSGN
 In children, the most common cause of acute
glomerulonephritis is post-streptococcal glomerulonephritis
 PSGN appears to be caused by glomerular immune complex
disease induced by specific nephritogenic strains of group A
beta-hemolytic streptococcus (GAS)
 The resulting glomerular immune complex disease triggers
complement activation and inflammation
 The latent period between GAS infection and PSGN is
dependent upon the site of infection: between one and three
weeks following GAS pharyngitis and between three and six
weeks following GAS skin infection
Clinical Presentation
History and Physical Exam
HISTORY
PertinentQuestionstoAsk
 Periorbital puffiness in the early morning
 Edema in legs in the evening
 The change in color, odor, consistency, and output of urine
 Recent upper respiratory tract or skin infection
 Fever, fatigue
 Headache and seizures
 Ulcers and rash on the extremities to rule out vasculitis
 Hemoptysis and dyspnea may be present in
 Goodpasture syndrome (due to cross-reacting antibodies to the alveolar
epithelium)
 GPA or MPA (if lungs are affected)
SYMPTOMS
 The classic symptoms of the nephritic syndrome are:
 Periorbital and pedal edema
 Hematuria with red or cola-colored urine
 Proteinuria in non-nephrotic range (i.e., less than 3.5 gm/day)
and may cause foamy urine when protein content is high
 Hypertension or poorly controlled blood pressure (BP) in
patients with previously controlled BP
 Seizures due to Hypertension
 Renal insufficiency characterized by oliguria (reduced urine
output), and azotemia, due to decreased glomerular filtration
rate (GFR)
Physical
Examination
 Patient may be Pale
 Elevated blood pressure.
 The signs of fluid overload may be present
 JVP distention
 Pitting edema
 Crackles on chest auscultation (pulmonary edema)
 On cardiovascular examination, a new heart murmur
can be auscultated in patients with infective
endocarditis.
 Palpable purpura and painful and swollen joints are
present in patients with systemic diseases like
vasculitis, Henoch-Schönlein purpura, and SLE.
Evaluation
 Urine analysis is the first step in the evaluation of
nephritic syndrome
 Urine can be discoloured by food, medication,
exercise, haemoglobinuria and myoglobinuria
 The upper limit of normal excretion of blood in the
urine is 3 RBCs/HPF
 In nephritic syndrome
 The urine has greater than 5 RBCs/ HPF along with
acanthocytes and dysmorphic RBCs
 RBCs casts and in a few cases WBCs casts
 Glomerular Hematuria is usually marked with
brownish (cola or tea) coloured urine
Evaluationof
Heamaturia
a b
Investigations
 U&Es, Creatinine
 Full Blood Count, PBS, ESR, C-reactive Protein
 Blood Culture
 ASOT, Anti-DNAse B
 Urine Culture and Microscopy for casts
 UPCR
 Throat Swab
 C3, C4
 ANA, Anti-dsDNA, ANCA, Anti-GBM
 KUB Ultrasound
 Kidney Biopsy (when indicated)
 RF to r/o cryoglobulinemia if suspected
 Hepatitis B Surface Antigen and HCV Antibodies
Differential
Diagnosis
 The following renal diseases have a clinical
presentation similar to the nephritic
syndrome:
 Nephrotic syndrome – FSGS, ICGN
 Familial nephritis – Alports, Thin Basement
Membrane Disease
 Idiopathic hematuria
 Anaphylaxis
Treatment
 The treatment is mainly supportive and consists of:
 Fluid and Dietary salt restriction
 If fluid overloaded, restrict intake to insensible losses only
 The reduced intake of sodium and potassium helps reduce the
retention of water
 Bed rest
 Antihypertensives
 Some patients may come in Hypertensive emergency and this
should be managed with drugs such as Labetalol, Sodium
Nitroprusside and Hydralazine
 In those who are not in hypertensive crisis, hypertension can be
treated with ACE inhibitors, ARBs, Amlodipine or Nifedipine
 Diuretics: Loop diuretics may be administered to excrete
excess sodium and water retained in the body
 Corticosteroids: Help relieve the inflammation in the kidney
and promote healing. This is indicated in patients with RPGN
Treatment
 Immunomodulators: Immunosuppressive drugs reduce and
block the antigenic effects of the inciting agents especially in
RPGN
 Use of corticosteroids and immunomodulators is controversial in
certain causes of the nephritic syndrome, including staphylococcal
endocarditis. It can aggravate the sepsis and result in increased
mortality
 Antibiotics: Post streptococcal GN patients with evidence of
streptococcal infection are administered penicillin. Erythromycin
is preferred for patients allergic to penicillin.
 Dialysis: In some cases, the disease has a fulminating course
leading to severe AKI requiring renal replacement therapy.
Complications
 The nephritic syndrome can grossly compromise
renal function and lead to the following
complications.
 Acute Kidney Injury and progression to RPGN
 Uncontrolled hypertension
 Azotemia
 Hyperkalemia
 Hyperphosphatemia
 Hypocalcemia
 Heart failure
 Hypertensive encephalopathy presenting as seizures and
altered consciousness
Prognosis
 The prognosis of the nephritic syndrome depends
upon the underlying aetiology, age of the patients
and timely intervention
 APSGN is the commonest in children and has
excellent outcome
 Adults typically have a chronic fulminating course.
 The disease is not resolved in 20 to 74% of the adults
 In these patients, the renal function derangement
persists and will result in Chronic Kidney Disease
SUMMARY
 The nephritic syndrome is a common presentation of most proliferative glomerulonephritides (GN) and
is characterised by haematuria, oliguria, hypertension and edema
 The primary pathology can be in the kidney, or it can be a consequence of systemic disorders
 Poststrep GN is the commonest cause of Nephritic Syndrome in children and has a good prognosis
 Nephritic syndrome may have a variable clinical picture depending on the underlying aetiology
 The acanthocytes, dysmorphic red blood cells, and RBC casts are pathognomonic of glomerular
inflammation
 The severity of clinical symptoms at the time of presentation determines the prognosis of the disease
 Patients with severe oliguria, azotemia, raised creatinine level at the time of presentation have a worse
prognosis.
 Supportive treatment should be initiated immediately along with carrying out the evaluation tests for a
specific diagnosis
Nephrotic Syndromein Children
Outline
1. Introduction
2. Epidemiology
3. Classification
4. Pathogenesis and Pathophysiology
5. Clinical Presentation
6. Complications
7. Investigations
8. Management
Scenario
 5 year old presents with generalized body
swelling is referred to the ER.
 His lab tests are as follows:
 Urine 4+ proteinuria; Serum albumin 17mmol/l
Cholesterol 12mmol/l; Creatinine 38umol/l; BP 90/60
 Questions
 Take relevant history
 What is the most likely diagnosis
 What are the possible aetiologies?
 What further investigations would like to do?
INTRODUCTION
 Nephrotic Syndrome is the commonest
glomerular disease in children
 It manifests with oedema, hypoalbuminemia,
heavy proteinuria and hyperlipidaemia.
Epidemiology
 Incidence 2-7/100000 Children per year - Nandlal
L. et al-2019
 Sex predilection Male:Female 2:1
 Commonly affects Children between 2- 10 years.
Definition:NephroticSyndrome
Nephrotic Range Proteinuria
UPCR ≥ 200 mg/mmol (2 mg/mg) in 1st morning void, or 24hr urine
sample ≥ 1000 mg/m2 per day corresponding to 3 + or 4 + by urine
dipstick
Hypoalbuminemia
Serum Alb <30g/L
OR
Edema
When serum albumin is
not available
Classification
 Congenital Nephrotic Syndrome
 Manifests in the first 3 months of life
 Infantile N.S
 Manifests after 3 months of life but before 12 months of
life
 Primary/Idiopathic NS
 Most common and cause is unknown
 Secondary NS
 Has an identifiable cause
 Can present at any age
1. Idiopathic 85% of cases
2. Genetics
3. Infections e.g Syphilis, malaria,toxoplasimosis,schistosomiasis
4.Drugs NSAIDS, Lithium, Mercury, Lead.
5. Autoimmune and connective tissue disorders e.g, SLE, Granulomatosus with
Polyangiitis, Microscopic polyangiitis, IgA nephropathy
6. Malignancies; Lymphoma, leukemia
CAUSES OF CHILDHOOD NEPHROTIC SYNDROME
IdiopathicNS
 Commonest form of NS
 Affecting from 1.15 to 16.9 per 100,000 children per year
globally
 85–90% are Steroid Sensitive (SSNS)
 70–80% will have at least one relapse during follow-up
 50% of these will experience frequent relapses (FRNS) or
become Steroid dependent (SDNS)
 10–30% continue to have a relapsing course into young
adulthood
 A small percentage will show no response to steroid therapy
of which some will progress to ESKD
Pathogenesis
and
Pathophysiology
 The podocyte is a polarised epithelial cell with
interdigitating foot processes with a unique cell–cell
junction known as the slit diaphragm
 The podocyte, along with the glomerular basement
membrane and the fenestrated glomerular
endothelium, forms a trilayered structure— the
glomerular filtration barrier
 The podocyte and filtration barrier allow an
ultrafiltrate almost completely devoid of protein to
pass into the Bowman’s space and proceed onto
the proximal tubule
Normal
 Podocyte architecture is maintained by an extensive
actin cytoskeleton that enables the glomerular filtration
barrier to withstand the substantial capillary hydrostatic
pressure
 Loss of normal podocyte structure, the foot processes
or the slit diaphragm that spans these interdigitations
can lead to loss of albumin in the ultrafiltrate
 Podocytes are terminally differentiated cells with
minimal regeneration and thus, vulnerable to injury
Abnormal
Pathogenesis
and
Pathophysiology
lecture notes
Pathophysiology
25-Jul-23
Edema:
 Under fill theory: hypoalbuminemia
 Over fill theory:↑ tubular NaCl reabsorption
secondary to RAAS → intravascular expansion
→ fluid shift following pressure gradient
 Hypercholesterolemia
 hypoproteinemia → hepatic lipoprotein
synthesis
→ ↑serum lipid (cholesterol, lipoprotein) → lipid
metabolism
25-Jul-23
 Sudden onset of dependent pitting oedema
 Periorbital
 scrotal or vulva
 ankle or leg
 Weight gain
 Ascites
 abdominal pain
 Diarrhea (due to intestinal oedema)
 Respiratory distress (due to pulmonary edema/
pleural effusions or massive ascites)
 Decreased urine output
 ±HTN and Hematuria
Clinical
Manifestation
25-Jul-23
Infection
Spontaneous bacterial peritonitis, cellulitis,
bacteriemia (S.pneumoniae, E.coli)
Steroid and immunosuppressant toxicity
Hypovolaemia
abdominal pain and may feel faint, cold
peripheries, poor pulse volume, hypotension, and
haemoconcentration.
A low urinary sodium (<20mmol/L) and a high
packed cell volume
Complications
 Thromboembolism
Hypercoagulable state due to decreased
fibrinolytic factors (urinary losses of antithrombin
III, proteins C and S)
Thrombocytosis
exacerbated by steroid therapy
Increased synthesis of clotting factors
Increased blood viscosity from the raised
haematocrit,
This is usually arterial and may affect the brain,
limbs and splanchnic circulation
 Hypercholesteroleamia
 Acute Kidney Injury (rare)
Complications
Approachtoa
SwollenChild
 First time or relapse???
 History of oedema noted on awakening in the morning or sudden swelling??
Distribution
Colour changes
Initiating factor? (bee sting)
Painful??
 Weight gain (edema)
 Respiratory distress (Breathlessness)
Infection, Pleural Effusion/Pulmonary Edema, Ascites
 Diarrhea
 Urine: frothy
 Past medical and drug history: recent illness, allergies, asthma
 Nutrition history
 Family history
History Taking
25-Jul-23
 Assessment of hydration status identifies fluid imbalances (dehydration,
overhydration)
 Blood pressure: hypertension
 Henoch-Schönlein purpura (purpura)
 Systemic lupus erythematosus (e.g. malar rash)
 Rales heard on lung auscultation suggest extravascular fluid from overload or
hypoalbuminemia
 Palpation and percussion of the abdomen may reveal ascites or masses
 Liver enlargement is present in several multisystem diseases (systemic lupus
erythematosus, infections, polycystic disease) and in glomerulosclerosis
Physical
Examination
Physical Examination
Differential
Diagnosis
 Nephrotic syndrome
 Protein losing enteropathy
 Hepatic failure
 Heart failure
 Acute/Chronic Glomerulonephritis
 Protein Energy Malnutrition
Lab
Investigations
 Urine Examination
 Full Blood Count & Blood picture
 Urine Analysis for Proteinuria
 Spot Urine Protein : Creatinine ratio
 Urinary protein excretion
 Liver Function Tests
 Renal Function Tests
25-Jul-23
Investigations
 Urinalysis
 - 3+ to 4+ proteinuria on dip sticks
 Spot UPC ratio > 2.0mg/mg (>0.2g/mmol)
 UPE > 40 mg/m2/hr
 Serum Creatinine – normal or elevated
 Serum albumin - < 30 g/L
 Serum Cholesterol/ TGA levels – elevated
Other
Investigations
Complement levels: decrease
suggest other than MCD
Antistreptolysin O titre and throat
swab
Hepatitis B antigen
Hepatitis C
RPR
Genetics when indicated
Kidney Biopsy when indicated
Management
InitialEpisode
 High protein diet
 Salt moderation
 Treatment of infections
 If significant edema – diuretics can be used but cautiously
 Mainstay of therapy is Corticosteroid treatment with Prednisolone
 First episode:
Prednisone 2mg/kg(60mg/m2) daily for 6weeks then taper
 Second episode:
Prednisone 2mg/kg(60mg/m2) until protein free for 3 days then taper
 Prevention:
Prednisone 1mg/kg daily x 5 days when URTI/Vaccines
Initial Episode
Treatment Related Definitions
• Complete remission
o UPCR (based on first morning void or 24 h urine sample) ≤ 20 mg/mmol (0.2
mg/mg) or < 100 mg/m2 per day, respectively, or negative or trace dipstick on
three or more consecutive days
• Steroid-sensitive nephrotic syndrome (SSNS)
o Complete remission within 4 weeks of PDN at standard dose (60 mg/m2/day or
2 mg/kg/day, maximum 60 mg/day)
• Steroid-resistant nephrotic syndrome (SRNS)
o Lack of complete remission within 4 weeks of treatment with PDN at standard
dose
• SSNS late responder
o A patient achieving complete remission during the confirmation period (i.e.
between 4 and 6 weeks of PDN therapy) for new onset NS
Treatment Related Definitions
• Infrequently relapsing Nephrotic Syndrome
o < 2 relapses in the 6 months following remission of the initial episode or <3
relapses in any subsequent 12-month period (modified definition)
• Frequently relapsing Nephrotic Syndrome (FRNS)
o ≥ 2 relapses in the first 6-months following remission of the initial episode or ≥
3 relapses in any 12 months (modified definition)
• Steroid-dependent nephrotic syndrome (SDNS)
o A patient with SSNS who experiences 2 consecutive relapses during
recommended Prednisolone therapy for first presentation or relapse or within
14 days of its discontinuation
Definition: Relapse
• Relapse
o Urine dipstick ≥3+ or UPCR ≥ 200 mg/mmol (≥ 2 mg/mg) on a spot urine sample
on 3 consecutive days, with or without reappearance of edema in a child who
had previously achieved complete remission
• Complicated Relapse (New Definition)
o A relapse requiring hospitalization due to one or more of the following: severe
edema, symptomatic hypovolemia or AKI requiring IV albumin infusions,
thrombosis, or severe infections (e.g., sepsis, peritonitis, pneumonia, cellulitis)
Treatment-Related Definitions: SSNS
• Steroid toxicity
o New or worsening obesity/overweight
o Sustained hypertension
o Hyperglycemia
o Behavioral/psychiatric disorders, sleep disruption
o Impaired statural growth (height velocity < 25th percentile and/or height
< 3rd percentile) in a child with normal growth before start of steroid
treatment
o Cushingoid features, striae rubrae/distensae,
o Glaucoma, ocular cataract
o Bone pain, avascular necrosis
 Mx of oedematous state
 Bed rest to be avoided as there is a tendency of hypercoagulability
 Dietary advice: no added salt, normal protein with adequate calories
 Prophylactic antibiotics: oral penicillin particularly in during relapse with
gross oedema
 Hypovolaemia: infuse salt poor albumin or 5% albumin, plasma protein
derivatives or human plasma.
• Note that the patient should be passing urine as you risk causing pulmonary oedema
• Diuretics: to be given cautiously
MANAGEMENT
• Symptomatic therapy:
 diuretic
 blood pressure control : ACEi (captopril, enalapril),
angiotensin II receptor antagonist
 hyperlipidaemia
• Immunosuppressive therapy:
Steroids
Levamisole
Cyclosporin, tacrolimus, mycophenolate mofetil
Cyclophosphamide
Rituximab
Management
ofSteroid
ResistantNS
Steroidtoxicity
• Stunting of growth
• Cataracts
• Striae
• Severe cushingoid features
• behavioural changes, a rounded face, central obesity
and the tendency to bruise more easily, hirsutism
• Osteoporosis
• Proximal myopathy
• Recurrent infection due low immunity
SteroidToxicity
OtherMedication
togivewhen
givingSteroid
Therapy
 Proton pump Inhibitor
 Omeprazole
 Lansoprazole
 Calcium
 Vit D
Managementof
Complications
 Infection: parenteral penicillin and a third
generation cephalosporin (in primary
peritonitis)
 If exposed to chickenpox and measles
varicella-zoster immunoglobulin (VZIG) should
be given within 72 hours after exposure to
chickenpox / single dose of intravenous
immunoglobulin
 Thrombosis : Warfarin, low-dose aspirin, and
dipyridamole all have been used to minimize
the risk of clots.
25-Jul-23
EDUCATION
 Parents and school teachers should be
provided with information regarding the disease
which includes:
1. Advice and precaution of infection
2. Danger of sudden steroid withdrawal (adrenal
crisis)
3. Immunization:
 While the child is on corticosteroid treatment and
within 6 weeks after its cessation, only killed
vaccines may be safely administered to the child.
 Live vaccines can be administered 6 weeks after
cessation of corticosteroid therapy
Vaccines
Haemophilus
Prevenar/Pneumovax given
 Less concern about prophylactic
Penicillin
 Less effective if vaccinate on
Prednisone in terms of building up
immunity
PROGNOSIS
Idiopathic NS
Steroid sensitive (90%)
Frequent
relapses/S.dependent (50%)
Infrequent relapses (33%)
No relapses (25%)
Steroid resistant (10%)
ESKD
25-Jul-23
How do you
prevent a
Heart Attack?
THE END

More Related Content

PPTX
Portal Hypertension in children
PPTX
Hematuria in children
PPTX
Hiv associated nephropathy (hivan)
PDF
hyponatremia
PPTX
Intussusception in children
PPTX
Psychogenic Polydipsia
Portal Hypertension in children
Hematuria in children
Hiv associated nephropathy (hivan)
hyponatremia
Intussusception in children
Psychogenic Polydipsia

What's hot (20)

PPTX
Haemolytic uremic syndrome
PPTX
Nephrotic syndrome
PPTX
Acute Renal Failure in Neonates
PPTX
Approach to Hematuria
PPTX
Hyponatremia
PDF
Approch to Hematuria in pediatric age group
PPT
DKA in children
PPTX
Bleeding Per Rectum In Children
PPTX
Acute kidney injury in children 2018
PPT
Hyperkalemia in children
PPTX
Approach to chronic diarrhea
PPTX
Acute Nephritic Syndromes
PDF
Heart failure in children 2021
PPTX
Upper GI Bleeding
PPTX
Hyponatremia
PPT
Hematuria In Children
PPTX
Juvenile Colonic Polyp
PPSX
Hepatorenal Syndrome
PPTX
Post streptococcal glomerulonephritis
PPT
Upper GI Bleeds
Haemolytic uremic syndrome
Nephrotic syndrome
Acute Renal Failure in Neonates
Approach to Hematuria
Hyponatremia
Approch to Hematuria in pediatric age group
DKA in children
Bleeding Per Rectum In Children
Acute kidney injury in children 2018
Hyperkalemia in children
Approach to chronic diarrhea
Acute Nephritic Syndromes
Heart failure in children 2021
Upper GI Bleeding
Hyponatremia
Hematuria In Children
Juvenile Colonic Polyp
Hepatorenal Syndrome
Post streptococcal glomerulonephritis
Upper GI Bleeds
Ad

Similar to lecture notes (20)

PPTX
GR 11 NEPHROTIC AND NEPHRITIC SYNDROME.pptx
PPTX
Glomerulonephritis power point presentation
PPTX
Glomerulonephritis - Acute Nephritic Syndromes
PPTX
NS and NS.pptx
PPTX
NS and NS.pptx
PPT
17--nephropathy{17}.ppt
PDF
NEPHRITIC SYNDROME.Nephritic syndrome is a kidney disorder characterized
PPTX
Nephrotic & Nephritic Syndromes in Children.pptx
PPT
20100603 acute glomerulonephritis
PPTX
AGN.pptx7777777777777777777777777777777777777777777
PPTX
Autonomic nervous system : physiology to management of diseases
PPT
19 Acute Glomerulonephritis
PPTX
Nephrotic syndrome
PPT
Nephrotic presentation.ppt9999999999999999999999999999999999999
PPTX
Acute Glomerulonephritis
PPTX
Glomorular disease B.pptx
PPTX
Acute Nephritic Syndrome VKP.pptx
PPTX
nephritis.bsc nursing third year kcon....
PPTX
GLOMERULONEPHRITIS disease description pptx
PPT
Acute glomerular disease
GR 11 NEPHROTIC AND NEPHRITIC SYNDROME.pptx
Glomerulonephritis power point presentation
Glomerulonephritis - Acute Nephritic Syndromes
NS and NS.pptx
NS and NS.pptx
17--nephropathy{17}.ppt
NEPHRITIC SYNDROME.Nephritic syndrome is a kidney disorder characterized
Nephrotic & Nephritic Syndromes in Children.pptx
20100603 acute glomerulonephritis
AGN.pptx7777777777777777777777777777777777777777777
Autonomic nervous system : physiology to management of diseases
19 Acute Glomerulonephritis
Nephrotic syndrome
Nephrotic presentation.ppt9999999999999999999999999999999999999
Acute Glomerulonephritis
Glomorular disease B.pptx
Acute Nephritic Syndrome VKP.pptx
nephritis.bsc nursing third year kcon....
GLOMERULONEPHRITIS disease description pptx
Acute glomerular disease
Ad

Recently uploaded (20)

PPTX
Virtual and Augmented Reality in Current Scenario
PDF
Vision Prelims GS PYQ Analysis 2011-2022 www.upscpdf.com.pdf
PDF
FOISHS ANNUAL IMPLEMENTATION PLAN 2025.pdf
PPTX
A powerpoint presentation on the Revised K-10 Science Shaping Paper
PDF
CISA (Certified Information Systems Auditor) Domain-Wise Summary.pdf
PDF
advance database management system book.pdf
DOCX
Cambridge-Practice-Tests-for-IELTS-12.docx
PPTX
CHAPTER IV. MAN AND BIOSPHERE AND ITS TOTALITY.pptx
PDF
Paper A Mock Exam 9_ Attempt review.pdf.
PPTX
202450812 BayCHI UCSC-SV 20250812 v17.pptx
PDF
Uderstanding digital marketing and marketing stratergie for engaging the digi...
PDF
International_Financial_Reporting_Standa.pdf
PPTX
ELIAS-SEZIURE AND EPilepsy semmioan session.pptx
PDF
Chinmaya Tiranga quiz Grand Finale.pdf
PPTX
History, Philosophy and sociology of education (1).pptx
PDF
IGGE1 Understanding the Self1234567891011
PDF
FORM 1 BIOLOGY MIND MAPS and their schemes
PDF
Trump Administration's workforce development strategy
PDF
BP 704 T. NOVEL DRUG DELIVERY SYSTEMS (UNIT 1)
PPTX
Chinmaya Tiranga Azadi Quiz (Class 7-8 )
Virtual and Augmented Reality in Current Scenario
Vision Prelims GS PYQ Analysis 2011-2022 www.upscpdf.com.pdf
FOISHS ANNUAL IMPLEMENTATION PLAN 2025.pdf
A powerpoint presentation on the Revised K-10 Science Shaping Paper
CISA (Certified Information Systems Auditor) Domain-Wise Summary.pdf
advance database management system book.pdf
Cambridge-Practice-Tests-for-IELTS-12.docx
CHAPTER IV. MAN AND BIOSPHERE AND ITS TOTALITY.pptx
Paper A Mock Exam 9_ Attempt review.pdf.
202450812 BayCHI UCSC-SV 20250812 v17.pptx
Uderstanding digital marketing and marketing stratergie for engaging the digi...
International_Financial_Reporting_Standa.pdf
ELIAS-SEZIURE AND EPilepsy semmioan session.pptx
Chinmaya Tiranga quiz Grand Finale.pdf
History, Philosophy and sociology of education (1).pptx
IGGE1 Understanding the Self1234567891011
FORM 1 BIOLOGY MIND MAPS and their schemes
Trump Administration's workforce development strategy
BP 704 T. NOVEL DRUG DELIVERY SYSTEMS (UNIT 1)
Chinmaya Tiranga Azadi Quiz (Class 7-8 )

lecture notes

  • 1. Glomerulonephritides (Nephritic and Nephrotic) Dr Paul Mashanga Paediatric Nephrologist
  • 2. Case  A 9 yr old presents with h/o of seizures for 1 day. Mom gives a history that the boy was well until 2 days ago when he started c/o a headache, swelling of feet and eyes, and passing tea colored urine. No h/o travel but mom says the boy had sore throat 2 weeks ago
  • 3. Introduction  Glomerulonephritis, as the term states, is inflammation of the glomerulus  Acute Glomerular injury with the following features:  Haematuria (Microscopic or Macroscopic)  Hypertension (due to water and salt retention)  AKI (Oliguria, Uraemia, elevated creatinine)  Oedema (Peripheral or Pulmonary)  The major underlying pathology is inflammation of the glomerulus  The primary pathology can be in the kidney, or it can be a consequence of systemic disorders
  • 4. Etiology Causative agent Examples Post-Infectious (Immune complex mediated following infection) Bacterial Post-Streptococcal (80% of cases) S. aureus, S. pneumoniae, M, pneumoiae, E. coli, Sypilis, TB Viral EBV, CMV, HSV, VZV, Hepatitis B and C, HIV Parasites Malaria, Schistosomiasis, Toxoplamosis, Trypanosomiasis Fungi Candida, Aspergillus, Cryptococcus, etc Autoimmune Immune Complex Mediated Systemic Lupus Erythematosus Ig A vasculitis (HSP) IgA Nephropathy Anti GBM antibodies Anti GBM Pauciimmune ANCA Vasculitis GPA, MPA
  • 5. Pathophysiology  Depends on the underlying cause  There is a structural disruption of the glomerular basement membrane  Glomerular filtration barrier (GFB) is formed by a meshwork of laminin, proteoglycans, and type IV collagen  The GFB allows the filtration of water and small and medium-sized solutes  The three layers of the glomerular filtration barrier are the endothelium, glomerular basement membrane (GBM), and podocytes
  • 7. Pathophysiology  The GFB can be damaged by various mechanisms  Direct damage to the endothelial cell layer  Deposition of immune complex in subendothelial, subepithelial, and mesangial space  Disruption of glomerular basement membrane by primary renal or secondary systemic diseases  Damage to the podocytes' cellular layer
  • 8. Pathophysiology ofAPSGN  In children, the most common cause of acute glomerulonephritis is post-streptococcal glomerulonephritis  PSGN appears to be caused by glomerular immune complex disease induced by specific nephritogenic strains of group A beta-hemolytic streptococcus (GAS)  The resulting glomerular immune complex disease triggers complement activation and inflammation  The latent period between GAS infection and PSGN is dependent upon the site of infection: between one and three weeks following GAS pharyngitis and between three and six weeks following GAS skin infection
  • 10. HISTORY PertinentQuestionstoAsk  Periorbital puffiness in the early morning  Edema in legs in the evening  The change in color, odor, consistency, and output of urine  Recent upper respiratory tract or skin infection  Fever, fatigue  Headache and seizures  Ulcers and rash on the extremities to rule out vasculitis  Hemoptysis and dyspnea may be present in  Goodpasture syndrome (due to cross-reacting antibodies to the alveolar epithelium)  GPA or MPA (if lungs are affected)
  • 11. SYMPTOMS  The classic symptoms of the nephritic syndrome are:  Periorbital and pedal edema  Hematuria with red or cola-colored urine  Proteinuria in non-nephrotic range (i.e., less than 3.5 gm/day) and may cause foamy urine when protein content is high  Hypertension or poorly controlled blood pressure (BP) in patients with previously controlled BP  Seizures due to Hypertension  Renal insufficiency characterized by oliguria (reduced urine output), and azotemia, due to decreased glomerular filtration rate (GFR)
  • 12. Physical Examination  Patient may be Pale  Elevated blood pressure.  The signs of fluid overload may be present  JVP distention  Pitting edema  Crackles on chest auscultation (pulmonary edema)  On cardiovascular examination, a new heart murmur can be auscultated in patients with infective endocarditis.  Palpable purpura and painful and swollen joints are present in patients with systemic diseases like vasculitis, Henoch-Schönlein purpura, and SLE.
  • 13. Evaluation  Urine analysis is the first step in the evaluation of nephritic syndrome  Urine can be discoloured by food, medication, exercise, haemoglobinuria and myoglobinuria  The upper limit of normal excretion of blood in the urine is 3 RBCs/HPF  In nephritic syndrome  The urine has greater than 5 RBCs/ HPF along with acanthocytes and dysmorphic RBCs  RBCs casts and in a few cases WBCs casts  Glomerular Hematuria is usually marked with brownish (cola or tea) coloured urine
  • 15. Investigations  U&Es, Creatinine  Full Blood Count, PBS, ESR, C-reactive Protein  Blood Culture  ASOT, Anti-DNAse B  Urine Culture and Microscopy for casts  UPCR  Throat Swab  C3, C4  ANA, Anti-dsDNA, ANCA, Anti-GBM  KUB Ultrasound  Kidney Biopsy (when indicated)  RF to r/o cryoglobulinemia if suspected  Hepatitis B Surface Antigen and HCV Antibodies
  • 16. Differential Diagnosis  The following renal diseases have a clinical presentation similar to the nephritic syndrome:  Nephrotic syndrome – FSGS, ICGN  Familial nephritis – Alports, Thin Basement Membrane Disease  Idiopathic hematuria  Anaphylaxis
  • 17. Treatment  The treatment is mainly supportive and consists of:  Fluid and Dietary salt restriction  If fluid overloaded, restrict intake to insensible losses only  The reduced intake of sodium and potassium helps reduce the retention of water  Bed rest  Antihypertensives  Some patients may come in Hypertensive emergency and this should be managed with drugs such as Labetalol, Sodium Nitroprusside and Hydralazine  In those who are not in hypertensive crisis, hypertension can be treated with ACE inhibitors, ARBs, Amlodipine or Nifedipine  Diuretics: Loop diuretics may be administered to excrete excess sodium and water retained in the body  Corticosteroids: Help relieve the inflammation in the kidney and promote healing. This is indicated in patients with RPGN
  • 18. Treatment  Immunomodulators: Immunosuppressive drugs reduce and block the antigenic effects of the inciting agents especially in RPGN  Use of corticosteroids and immunomodulators is controversial in certain causes of the nephritic syndrome, including staphylococcal endocarditis. It can aggravate the sepsis and result in increased mortality  Antibiotics: Post streptococcal GN patients with evidence of streptococcal infection are administered penicillin. Erythromycin is preferred for patients allergic to penicillin.  Dialysis: In some cases, the disease has a fulminating course leading to severe AKI requiring renal replacement therapy.
  • 19. Complications  The nephritic syndrome can grossly compromise renal function and lead to the following complications.  Acute Kidney Injury and progression to RPGN  Uncontrolled hypertension  Azotemia  Hyperkalemia  Hyperphosphatemia  Hypocalcemia  Heart failure  Hypertensive encephalopathy presenting as seizures and altered consciousness
  • 20. Prognosis  The prognosis of the nephritic syndrome depends upon the underlying aetiology, age of the patients and timely intervention  APSGN is the commonest in children and has excellent outcome  Adults typically have a chronic fulminating course.  The disease is not resolved in 20 to 74% of the adults  In these patients, the renal function derangement persists and will result in Chronic Kidney Disease
  • 21. SUMMARY  The nephritic syndrome is a common presentation of most proliferative glomerulonephritides (GN) and is characterised by haematuria, oliguria, hypertension and edema  The primary pathology can be in the kidney, or it can be a consequence of systemic disorders  Poststrep GN is the commonest cause of Nephritic Syndrome in children and has a good prognosis  Nephritic syndrome may have a variable clinical picture depending on the underlying aetiology  The acanthocytes, dysmorphic red blood cells, and RBC casts are pathognomonic of glomerular inflammation  The severity of clinical symptoms at the time of presentation determines the prognosis of the disease  Patients with severe oliguria, azotemia, raised creatinine level at the time of presentation have a worse prognosis.  Supportive treatment should be initiated immediately along with carrying out the evaluation tests for a specific diagnosis
  • 23. Outline 1. Introduction 2. Epidemiology 3. Classification 4. Pathogenesis and Pathophysiology 5. Clinical Presentation 6. Complications 7. Investigations 8. Management
  • 24. Scenario  5 year old presents with generalized body swelling is referred to the ER.  His lab tests are as follows:  Urine 4+ proteinuria; Serum albumin 17mmol/l Cholesterol 12mmol/l; Creatinine 38umol/l; BP 90/60  Questions  Take relevant history  What is the most likely diagnosis  What are the possible aetiologies?  What further investigations would like to do?
  • 25. INTRODUCTION  Nephrotic Syndrome is the commonest glomerular disease in children  It manifests with oedema, hypoalbuminemia, heavy proteinuria and hyperlipidaemia.
  • 26. Epidemiology  Incidence 2-7/100000 Children per year - Nandlal L. et al-2019  Sex predilection Male:Female 2:1  Commonly affects Children between 2- 10 years.
  • 27. Definition:NephroticSyndrome Nephrotic Range Proteinuria UPCR ≥ 200 mg/mmol (2 mg/mg) in 1st morning void, or 24hr urine sample ≥ 1000 mg/m2 per day corresponding to 3 + or 4 + by urine dipstick Hypoalbuminemia Serum Alb <30g/L OR Edema When serum albumin is not available
  • 28. Classification  Congenital Nephrotic Syndrome  Manifests in the first 3 months of life  Infantile N.S  Manifests after 3 months of life but before 12 months of life  Primary/Idiopathic NS  Most common and cause is unknown  Secondary NS  Has an identifiable cause  Can present at any age
  • 29. 1. Idiopathic 85% of cases 2. Genetics 3. Infections e.g Syphilis, malaria,toxoplasimosis,schistosomiasis 4.Drugs NSAIDS, Lithium, Mercury, Lead. 5. Autoimmune and connective tissue disorders e.g, SLE, Granulomatosus with Polyangiitis, Microscopic polyangiitis, IgA nephropathy 6. Malignancies; Lymphoma, leukemia CAUSES OF CHILDHOOD NEPHROTIC SYNDROME
  • 30. IdiopathicNS  Commonest form of NS  Affecting from 1.15 to 16.9 per 100,000 children per year globally  85–90% are Steroid Sensitive (SSNS)  70–80% will have at least one relapse during follow-up  50% of these will experience frequent relapses (FRNS) or become Steroid dependent (SDNS)  10–30% continue to have a relapsing course into young adulthood  A small percentage will show no response to steroid therapy of which some will progress to ESKD
  • 32.  The podocyte is a polarised epithelial cell with interdigitating foot processes with a unique cell–cell junction known as the slit diaphragm  The podocyte, along with the glomerular basement membrane and the fenestrated glomerular endothelium, forms a trilayered structure— the glomerular filtration barrier  The podocyte and filtration barrier allow an ultrafiltrate almost completely devoid of protein to pass into the Bowman’s space and proceed onto the proximal tubule Normal
  • 33.  Podocyte architecture is maintained by an extensive actin cytoskeleton that enables the glomerular filtration barrier to withstand the substantial capillary hydrostatic pressure  Loss of normal podocyte structure, the foot processes or the slit diaphragm that spans these interdigitations can lead to loss of albumin in the ultrafiltrate  Podocytes are terminally differentiated cells with minimal regeneration and thus, vulnerable to injury Abnormal
  • 36. Pathophysiology 25-Jul-23 Edema:  Under fill theory: hypoalbuminemia  Over fill theory:↑ tubular NaCl reabsorption secondary to RAAS → intravascular expansion → fluid shift following pressure gradient  Hypercholesterolemia  hypoproteinemia → hepatic lipoprotein synthesis → ↑serum lipid (cholesterol, lipoprotein) → lipid metabolism
  • 37. 25-Jul-23  Sudden onset of dependent pitting oedema  Periorbital  scrotal or vulva  ankle or leg  Weight gain  Ascites  abdominal pain  Diarrhea (due to intestinal oedema)  Respiratory distress (due to pulmonary edema/ pleural effusions or massive ascites)  Decreased urine output  ±HTN and Hematuria Clinical Manifestation
  • 38. 25-Jul-23 Infection Spontaneous bacterial peritonitis, cellulitis, bacteriemia (S.pneumoniae, E.coli) Steroid and immunosuppressant toxicity Hypovolaemia abdominal pain and may feel faint, cold peripheries, poor pulse volume, hypotension, and haemoconcentration. A low urinary sodium (<20mmol/L) and a high packed cell volume Complications
  • 39.  Thromboembolism Hypercoagulable state due to decreased fibrinolytic factors (urinary losses of antithrombin III, proteins C and S) Thrombocytosis exacerbated by steroid therapy Increased synthesis of clotting factors Increased blood viscosity from the raised haematocrit, This is usually arterial and may affect the brain, limbs and splanchnic circulation  Hypercholesteroleamia  Acute Kidney Injury (rare) Complications
  • 41.  First time or relapse???  History of oedema noted on awakening in the morning or sudden swelling?? Distribution Colour changes Initiating factor? (bee sting) Painful??  Weight gain (edema)  Respiratory distress (Breathlessness) Infection, Pleural Effusion/Pulmonary Edema, Ascites  Diarrhea  Urine: frothy  Past medical and drug history: recent illness, allergies, asthma  Nutrition history  Family history History Taking
  • 42. 25-Jul-23  Assessment of hydration status identifies fluid imbalances (dehydration, overhydration)  Blood pressure: hypertension  Henoch-Schönlein purpura (purpura)  Systemic lupus erythematosus (e.g. malar rash)  Rales heard on lung auscultation suggest extravascular fluid from overload or hypoalbuminemia  Palpation and percussion of the abdomen may reveal ascites or masses  Liver enlargement is present in several multisystem diseases (systemic lupus erythematosus, infections, polycystic disease) and in glomerulosclerosis Physical Examination Physical Examination
  • 43. Differential Diagnosis  Nephrotic syndrome  Protein losing enteropathy  Hepatic failure  Heart failure  Acute/Chronic Glomerulonephritis  Protein Energy Malnutrition
  • 44. Lab Investigations  Urine Examination  Full Blood Count & Blood picture  Urine Analysis for Proteinuria  Spot Urine Protein : Creatinine ratio  Urinary protein excretion  Liver Function Tests  Renal Function Tests 25-Jul-23
  • 45. Investigations  Urinalysis  - 3+ to 4+ proteinuria on dip sticks  Spot UPC ratio > 2.0mg/mg (>0.2g/mmol)  UPE > 40 mg/m2/hr  Serum Creatinine – normal or elevated  Serum albumin - < 30 g/L  Serum Cholesterol/ TGA levels – elevated
  • 46. Other Investigations Complement levels: decrease suggest other than MCD Antistreptolysin O titre and throat swab Hepatitis B antigen Hepatitis C RPR Genetics when indicated Kidney Biopsy when indicated
  • 48. InitialEpisode  High protein diet  Salt moderation  Treatment of infections  If significant edema – diuretics can be used but cautiously  Mainstay of therapy is Corticosteroid treatment with Prednisolone  First episode: Prednisone 2mg/kg(60mg/m2) daily for 6weeks then taper  Second episode: Prednisone 2mg/kg(60mg/m2) until protein free for 3 days then taper  Prevention: Prednisone 1mg/kg daily x 5 days when URTI/Vaccines Initial Episode
  • 49. Treatment Related Definitions • Complete remission o UPCR (based on first morning void or 24 h urine sample) ≤ 20 mg/mmol (0.2 mg/mg) or < 100 mg/m2 per day, respectively, or negative or trace dipstick on three or more consecutive days • Steroid-sensitive nephrotic syndrome (SSNS) o Complete remission within 4 weeks of PDN at standard dose (60 mg/m2/day or 2 mg/kg/day, maximum 60 mg/day) • Steroid-resistant nephrotic syndrome (SRNS) o Lack of complete remission within 4 weeks of treatment with PDN at standard dose • SSNS late responder o A patient achieving complete remission during the confirmation period (i.e. between 4 and 6 weeks of PDN therapy) for new onset NS
  • 50. Treatment Related Definitions • Infrequently relapsing Nephrotic Syndrome o < 2 relapses in the 6 months following remission of the initial episode or <3 relapses in any subsequent 12-month period (modified definition) • Frequently relapsing Nephrotic Syndrome (FRNS) o ≥ 2 relapses in the first 6-months following remission of the initial episode or ≥ 3 relapses in any 12 months (modified definition) • Steroid-dependent nephrotic syndrome (SDNS) o A patient with SSNS who experiences 2 consecutive relapses during recommended Prednisolone therapy for first presentation or relapse or within 14 days of its discontinuation
  • 51. Definition: Relapse • Relapse o Urine dipstick ≥3+ or UPCR ≥ 200 mg/mmol (≥ 2 mg/mg) on a spot urine sample on 3 consecutive days, with or without reappearance of edema in a child who had previously achieved complete remission • Complicated Relapse (New Definition) o A relapse requiring hospitalization due to one or more of the following: severe edema, symptomatic hypovolemia or AKI requiring IV albumin infusions, thrombosis, or severe infections (e.g., sepsis, peritonitis, pneumonia, cellulitis)
  • 52. Treatment-Related Definitions: SSNS • Steroid toxicity o New or worsening obesity/overweight o Sustained hypertension o Hyperglycemia o Behavioral/psychiatric disorders, sleep disruption o Impaired statural growth (height velocity < 25th percentile and/or height < 3rd percentile) in a child with normal growth before start of steroid treatment o Cushingoid features, striae rubrae/distensae, o Glaucoma, ocular cataract o Bone pain, avascular necrosis
  • 53.  Mx of oedematous state  Bed rest to be avoided as there is a tendency of hypercoagulability  Dietary advice: no added salt, normal protein with adequate calories  Prophylactic antibiotics: oral penicillin particularly in during relapse with gross oedema  Hypovolaemia: infuse salt poor albumin or 5% albumin, plasma protein derivatives or human plasma. • Note that the patient should be passing urine as you risk causing pulmonary oedema • Diuretics: to be given cautiously MANAGEMENT
  • 54. • Symptomatic therapy:  diuretic  blood pressure control : ACEi (captopril, enalapril), angiotensin II receptor antagonist  hyperlipidaemia • Immunosuppressive therapy: Steroids Levamisole Cyclosporin, tacrolimus, mycophenolate mofetil Cyclophosphamide Rituximab Management ofSteroid ResistantNS
  • 55. Steroidtoxicity • Stunting of growth • Cataracts • Striae • Severe cushingoid features • behavioural changes, a rounded face, central obesity and the tendency to bruise more easily, hirsutism • Osteoporosis • Proximal myopathy • Recurrent infection due low immunity
  • 57. OtherMedication togivewhen givingSteroid Therapy  Proton pump Inhibitor  Omeprazole  Lansoprazole  Calcium  Vit D
  • 58. Managementof Complications  Infection: parenteral penicillin and a third generation cephalosporin (in primary peritonitis)  If exposed to chickenpox and measles varicella-zoster immunoglobulin (VZIG) should be given within 72 hours after exposure to chickenpox / single dose of intravenous immunoglobulin  Thrombosis : Warfarin, low-dose aspirin, and dipyridamole all have been used to minimize the risk of clots. 25-Jul-23
  • 59. EDUCATION  Parents and school teachers should be provided with information regarding the disease which includes: 1. Advice and precaution of infection 2. Danger of sudden steroid withdrawal (adrenal crisis) 3. Immunization:  While the child is on corticosteroid treatment and within 6 weeks after its cessation, only killed vaccines may be safely administered to the child.  Live vaccines can be administered 6 weeks after cessation of corticosteroid therapy
  • 60. Vaccines Haemophilus Prevenar/Pneumovax given  Less concern about prophylactic Penicillin  Less effective if vaccinate on Prednisone in terms of building up immunity
  • 61. PROGNOSIS Idiopathic NS Steroid sensitive (90%) Frequent relapses/S.dependent (50%) Infrequent relapses (33%) No relapses (25%) Steroid resistant (10%) ESKD 25-Jul-23
  • 62. How do you prevent a Heart Attack?

Editor's Notes

  • #6: In immune complex–mediated diseases Antibody is produced against and combines with a circulating antigen that is usually unrelated to the kidney The immune complexes accumulate in GBMs and activate the complement system, leading to immune injury anti-GBM antibody disease Auto- antibodies are formed against Type IV collagen in the basement membrane
  • #9: Nephritogenic antigens  There are two leading candidates for the putative streptococcal antigen(s) responsible for PSGN Nephritis-associated plasmin receptor (NAPlr), a glycolytic enzyme, which has glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity. NAPlr has a plasmin-like activity which may promote a local inflammatory reaction. Streptococcal pyrogenic exotoxin B (SPE B), a cationic cysteine proteinase, has been localized in the subepithelial deposit
  • #18: angiotensin-converting enzyme (ACE) inhibitors should be used with caution due to the risk of hyperkalemia
  • #51: Rationale: Change in definitions was necessitated by the need to reduce exposure to Prednisolone